Sunitha is a seasoned executive with over 20 years of experience and brings to Melinta a wealth of CMC experience across small molecules, biologics, biosimilars, vaccines, cell/gene therapy and radiotherapeutic products. She brings a passion for helping patients, building strong teams and developing employees. Over the course of her career, she has contributed to the development, commercialization and lifecycle management of several new products and technologies.

Sunitha joins Melinta from Actinium Pharmaceuticals where she was the Senior Vice President, Technical Operations, and overseeing CDMO operations, Regulatory, Quality and Supply Chain functions. Prior to that, Sunitha was at Bristol-Myers Squibb in their Cell Therapy division, as Executive Director, Global Process Engineering where she was responsible for the global licensure of two autologous cell therapy products. Prior to BMS, Sunitha was at Kashiv BioSciences where she led approvals for biosimilar products. Prior to Kashiv, she held various leadership positions at Progenics Pharmaceuticals, Laureate Pharma and BioReliance.  

Sunitha earned her M.B.A. from the Kellogg School of Management at Northwestern University, a M.S. in Chemical Engineering from Penn State University, and a B.S. in Chemical Engineering from Coimbatore Institute of Technology in India. 

Fabrizio is a distinguished Medical Affairs leader with a proven track record of enabling successful medical and scientific advocacy and the translation of novel science into real-world clinical advances. Fabrizio received his MD degree at the University of Bologna and was a practicing physician before joining Merck in 1995. There, he worked in roles of growing managerial responsibility across different functions including sales, marketing, business development, medical affairs, and different therapeutic areas, with a particular focus on acute care and infectious diseases.  In 2020 he was appointed to lead the transition team to set up the medical affairs organization for the spin-off of Organon, where most recently, before joining Melinta, he acted as head of Global Medical Affairs and Outcomes Research.

Jisoo is a global pharmaceutical business development leader with a proven track record. Previously, Jisoo served as Vice President of Business Development and M&A at Covis Pharma. At Covis, Jisoo led global business development and M&A, including transformational buy-side and sell-side M&A, licensing and financings. In less than five years, Jisoo led seven deals worth roughly $2 billion in transaction value, helping expand the organization beyond the U.S. and into more than 50 markets.

Prior to Covis, he was an investment banker in J.P. Morgan’s Global Healthcare team in New York and San Francisco, where he advised companies in the pharmaceuticals, biotech and life sciences industries on M&A, equity and debt financings.

He holds a B.S. in Economics and Statistics from Carnegie Mellon University.

“Melinta is on a mission to make the most meaningful impact for patients with life-threatening illnesses and I’m excited to join the team in the middle of such great momentum. I look forward to working with this truly committed team toward continued growth and expansion to serve patients in need in the U.S. and beyond.”

Susan is a financial and accounting leader with more than 25 years of diverse experience strengthening corporate financial strategy, efficiencies, and controls. She’s been an integral part of Melinta’s financial and accounting team since 2016 and has served as CFO since April 2021.

In April 2024, Susan was appointed to the Board of Directors for BiomX, a public, clinical-stage company pioneering natural and engineered phage cocktails and personalized treatments to combat bacteria in chronic diseases. Susan brings her financial expertise to this role, serving as a member and chair of the audit committee.

Before joining Melinta, Susan served as Corporate Controller at Textura, where she oversaw the accounting function and played a lead IPO role with responsibility for centralizing accounting functions post-acquisition. Before Textura, she held leadership roles at Orbitz Worldwide, Inc., where she directed global technical accounting processes. And before that, Susan managed the SEC reporting and revenue functions at Facet Biotech and PDL BioPharma.

Susan began her career in public accounting at Ernst & Young, where she worked with a diverse client base ranging from large, public international SEC engagements to development-stage enterprises.

She holds a B.S. in Business Commerce, concentration in Accounting, from Santa Clara University and is a certified public accountant.

Jennifer is a seasoned life sciences industry executive with demonstrated success in general management, legal, and compliance.

Before Melinta, Jennifer held several leadership roles at The Medicines Company. She led legal and compliance counsel for multiple business units guiding commercial, medical, market access, and regulatory activities in those roles

Before The Medicines Company, Jennifer was an attorney at Porzio, Bromberg & Newman, P.C., a law firm specializing in the life sciences industry. She advised pharmaceutical, medical device, and biotech companies on a variety of legal, regulatory, and compliance issues.

Jennifer holds a B.A. in History, magna cum laude, from New York University and a J.D. from the Rutgers School of Law, where she was managing editor of the Rutgers Law Review.